FDA Approves New Drug for HER2-Positive Breast Cancer |
News and Updates
eMediNexus Coverage from: 
FDA Approves New Drug for HER2-Positive Breast Cancer

0 Read Comments                

The FDA has approved tucatinib for treating advanced, HER2-positive breast cancer patients who have received at least one prior therapy.

The highly selective HER2-directed tyrosine kinase inhibitor, approved in combination with trastuzumab plus capecitabine, is indicated for patients with metastatic breast cancer or advanced but unresectable disease. Data from the HER2CLIMB study, which randomized 612 previously treated breast cancer patients 2:1 to trastuzumab and capecitabine plus either tucatinib or placebo, support the approval… (Medpage Today)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now